{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:56:38Z","timestamp":1772114198460,"version":"3.50.1"},"reference-count":41,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2021,8,3]]},"DOI":"10.1080\/14712598.2021.1869210","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T22:36:04Z","timestamp":1608762964000},"page":"1087-1096","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer"],"prefix":"10.1080","volume":"21","author":[{"given":"Dennis","family":"Mauricio","sequence":"first","affiliation":[{"name":"Department of Obstetrics, Gynecology, And Reproductive Sciences Yale University School of Medicine, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Harold","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology, And Reproductive Sciences Yale University School of Medicine, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan R.","family":"Tymon-Rosario","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology, And Reproductive Sciences Yale University School of Medicine, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burak","family":"Zeybek","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology, And Reproductive Sciences Yale University School of Medicine, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology, And Reproductive Sciences Yale University School of Medicine, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzl013"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.03.245"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1480"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.3672"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1097\/01.pai.00000141545.36485.d6"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02085"},{"key":"cit0007","unstructured":"Phase II anetumab ravtansine as 2nd line treatment for malignant pleural mesothelioma (MPM) - study results - clinicalTrials.gov [Internet]. [cited 2020Aug25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02610140."},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0693"},{"key":"cit0009","doi-asserted-by":"crossref","first-page":"B057","DOI":"10.1158\/1535-7163.TARG-19-B057","volume":"18","author":"Clarke J","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0487-T"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2005.04.017"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0582"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0789"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4009"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0337"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910500308"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)42180-6"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3476"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.136"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2015.07.008"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.20.11531"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00246-2"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604964"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0869"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0926"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.1684"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2938"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2016.11.002"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26135"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3973"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1111\/jog.14558"},{"key":"cit0032","unstructured":"Research C for DE and. FDA approves bevacizumab in combination with chemotherapy for ovarian cancer. FDA [Internet]. 2019 [cited 2020Aug29]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-bevacizumab-combination-chemotherapy-ovarian-cancer."},{"key":"cit0033","unstructured":"National Cancer Institute (NCI). A randomized phase 2 study of bevacizumab and either weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or platinum refractory ovarian cancer [internet]. clinicaltrials.gov; 2020 [cited 2020Aug25]. Report No.: NCT03587311. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03587311."},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.2174\/092986710794182999"},{"key":"cit0035","unstructured":"111Indium\u2010labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin - Hassan - 1999 - international journal of cancer - wiley online library [internet]. [cited 2020Aug27]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/%28SICI%291097-0215%2819990209%2980%3A4%3C559%3A%3AAID-IJC13%3E3.0.CO%3B2-Y."},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200007000-00011"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1891"},{"key":"cit0038","unstructured":"Bayer. An open-label phase Ib dose escalation study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and maximum tolerated dose of anetumab ravtansine in combination with pegylated liposomal doxorubicin 30 mg\/m2 given every 3 weeks in subjects with mesothelin-expressing platinum-resistant recurrent ovarian, fallopian tube or primary peritoneal cancer [internet]. clinicaltrials.gov; 2019 [cited 2020Aug25]. Report No.: NCT02751918. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02751918."},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-IGCS.322"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.2174\/2212697X03666160218215744"},{"key":"cit0041","unstructured":"Genentech, Inc. A phase I, open label study of the safety and pharmacokinetics of escalating doses of DMOT4039A in patients with unresectable pancreatic or platinum-resistant ovarian cancer [internet]. clinicaltrials.gov; 2017 [cited 2020Aug25]. S. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01469793."}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2021.1869210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T02:32:24Z","timestamp":1670553144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2021.1869210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,3]]}},"alternative-id":["10.1080\/14712598.2021.1869210"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2021.1869210","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}